The Aryavarth Express Hyderabad: At BioAsia 2026, themed “TechBio Unleashed: AI, Automation & the Biology Revolution,” inventors Dr Uday Saxena and Dr Markandey introduced their biotech venture, Utopia Therapeutics, along with its flagship nutraceutical products — Nexa Gut and Nexa Sweet.
Described as India-first innovations, the products are scheduled for launch in March after securing regulatory clearance from the Food Safety and Standards Authority of India (FSSAI).
Stem-Cell Attractant Technology for Gut Health
Highlighting the prevalence of digestive disorders in India, Dr Saxena noted that a significant portion of the population faces issues such as acidity, bloating, and low fibre intake. While conventional antacids and prebiotics offer temporary or partial relief, Nexa Gut is positioned as a deeper scientific solution.
According to the founders, the product combines prebiotic fibre with what they term “stem cell attractant technology.” The formulation is designed to naturally attract stem cells to the intestinal lining, supporting tissue renewal and long-term gut repair. They explained that the intestine undergoes continuous wear and tear, requiring sustained regeneration — a process the product aims to enhance.
Dr Markandey added that the nutraceutical has been developed under India’s BioIT Policy Biomanufacturing Hub framework and uses yeast-based enzyme technology. The formulation reportedly requires less than 10 milligrams of enzymes per bottle and is described by the company as a “non-chemical nutraceutical.”
Expanding Pipeline: From Metabolic Health to Obesity Vaccine
Beyond digestive health, Utopia Therapeutics plans to introduce six additional stem cell-based products targeting hair growth, skin conditions, detoxification, and metabolic health.
Among its most ambitious projects is a once-a-year preventive vaccine for obesity, currently protected by a US patent. With India ranking among the countries with high obesity prevalence, the founders say affordable biotechnology-driven interventions are urgently needed. Human trials for the obesity solution are projected in the coming years.
Backed by Biotech Accelerator Ecosystem
The innovation is supported by Whale Tank Accelerator, a biotech platform focused on scaling deep-science startups. Over the past three years, it has backed ventures working on pheromone-based crop protection technologies and advanced cancer therapeutics, including treatments for acute and chronic myeloid leukaemia.
The broader ecosystem is supported by the Department of Biotechnology and Biotechnology Industry Research Assistance Council (BIRAC), with the goal of transitioning India from a service-oriented biotech hub to a product-driven innovation economy.
With regulatory approval secured and commercial rollout planned for March, Nexa Gut and Nexa Sweet mark a significant step in India’s nutraceutical and biotech landscape. At BioAsia 2026, the company positioned itself as part of a growing movement where deep science, AI integration, and biomanufacturing are translating into market-ready healthcare solutions.
